Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Han W. Tun, MD, Liuyan Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139835

Published: 2020

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Craig B. Reeder, MD, Taimur Sher, MD, Vivek Roy, MD, Rahma M Warsame, MD, Victoria R. Alegria, Wilson I Gonsalves, MD, Prashant Kapoor, MD, David Dingli, MD PhD, Suzanne R. Hayman, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139559

Published: 2020

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Blood (2019) 134 (Supplement_1): 810.

https://doi.org/10.1182/blood-2019-126192

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

Association between Monoclonal Gammopathy and Rheumatoid Arthritis: A National Inpatient Sample (NIS) Study

Muhammad Azeem Khan, MD, Vagishwari Murugesan, MD, Hira Latif, MD, Muhamad Alhaj Moustafa, MD

Blood (2018) 132 (Supplement 1): 5599.

https://doi.org/10.1182/blood-2018-99-115672

Published: 2018

Journal Articles

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Muhamad Alhaj Moustafa, MD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Francis K Buadi, MD, Morie A Gertz, MD, Martha Q. Lacy, MD, Prashant Kapoor, MD, Suzanne R Hayman, MD, David Dingli, MD, PhD, Robert Kyle, MD, Shaji Kumar, MD

Blood (2014) 124 (21): 3427.

https://doi.org/10.1182/blood.V124.21.3427.3427

Published: 2014

NARROW

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Association between Monoclonal Gammopathy and Rheumatoid Arthritis: A National Inpatient Sample (NIS) Study

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only